Evan David Seigerman

Stock Analyst at BMO Capital

(3.25)
# 1,044
Out of 5,044 analysts
50
Total ratings
48.89%
Success rate
3.83%
Average return

Stocks Rated by Evan David Seigerman

Novo Nordisk
Oct 14, 2025
Maintains: Market Perform
Price Target: $50$55
Current: $52.05
Upside: +5.67%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215$240
Current: $227.54
Upside: +5.48%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600$640
Current: $654.48
Upside: -2.21%
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27$2
Current: $10.45
Upside: -80.86%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22$26
Current: $30.96
Upside: -16.02%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96$110
Current: $94.89
Upside: +15.92%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24$28
Current: $22.62
Upside: +23.78%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20$10
Current: $9.50
Upside: +5.26%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105$96
Current: $87.03
Upside: +10.31%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362$346
Current: $292.09
Upside: +18.46%
Maintains: Outperform
Price Target: $70$112
Current: $87.61
Upside: +27.84%
Maintains: Outperform
Price Target: $83$100
Current: $28.95
Upside: +245.42%
Reiterates: Outperform
Price Target: $33$36
Current: $24.50
Upside: +46.94%
Maintains: Outperform
Price Target: $9$3
Current: $5.60
Upside: -46.43%
Maintains: Outperform
Price Target: $369$396
Current: $820.10
Upside: -51.71%